GlassScriptPhysician profile
Earnest L Murray
NPI 1952597874
$79,030.55
in general payments reported to CMS, 2019-2025
47 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $2,090 · 2021: $15K · 2022: $19K · 2023: $12K · 2024: $8,627 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $7,378 · Honoraria: $6,325 · Travel and Lodging: $58.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,362.50 |
| Food and Beverage | $7,378.38 |
| Honoraria | $6,325.00 |
| Travel and Lodging | $58.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $57,394.05 | 2020-2025 | |
| Axsome Therapeutics, INC. | $6,458.83 | 2025 | Symbravo |
| Allergan, INC. | $5,839.24 | 2019-2022 | |
| Pfizer INC. | $1,566.39 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $1,425.64 | 2019-2025 | |
| Ucb, INC. | $642.54 | 2022-2025 | Rystiggo, Nayzilam, Briviact |
| Celgene Corporation | $576.97 | 2021-2025 | Zeposia |
| Biogen, INC. | $515.25 | 2020-2025 | Vumerity, Tysabri, Skyclarys |
| Amneal Pharmaceuticals LLC | $299.51 | 2022-2025 | Rytary, Crexont, Ongentys |
| Teva Pharmaceuticals USA, INC. | $295.60 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Emd Serono, INC. | $295.34 | 2019-2025 | Mavenclad |
| Acadia Pharmaceuticals INC | $283.41 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $277.92 | 2019-2024 | Ultomiris, Soliris |
| Sunovion Pharmaceuticals INC. | $239.14 | 2019-2021 | |
| Sk Life Science, INC. | $235.93 | 2020-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earnest Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.